US Patent 9,655,843 analysis: scope and claim coverage for mucoadhesive biodegradable buprenorphine buccal delivery with unidirectional diffusion and pH-controlled polymer diffusion
What is the inventive concept in US 9,655,843 and what does it cover?
US 9,655,843 claims a mucoadhesive, biodegradable, multilayer buccal delivery system for buprenorphine that uses (i) a polymeric “diffusion environment” with a specified pH window, (ii) an adjacent polymeric “barrier environment,” and (iii) a “unidirectional diffusion gradient” upon application to the buccal surface. The claims cover both:
- Methods of delivering buprenorphine (transmucosal/buccal administration).
- The device itself (layered structure).
- A method of treating pain via adherence of the device to the buccal surface.
The claim spine is consistent across independent and dependent claims:
- Device modality: “mucoadhesive biodegradable drug delivery device for transmucosal delivery” with a “bioerodible mucoadhesive layer.”
- Drug placement: buprenorphine is disposed in a polymeric diffusion environment.
- pH limitation: the diffusion environment has a pH between about 4 and about 7.5 (with dependent claims narrowing to about 4 to about 6, and “buffered” embodiments).
- Multilayer / barrier: a polymeric barrier environment disposed adjacent to the mucoadhesive layer.
- Diffusion directionality: the system provides a unidirectional diffusion gradient upon application to a buccal surface.
- Optional claim add-ons: specific polymer classes (film-forming water-erodible adhesive + bioadhesive polymers), optional opioid antagonist in the barrier environment, and optional third layer/coating.
Claim scope summary (practical infringement lens)
The claims are not limited to buprenorphine form (free base vs salt) in the text you provided, but they tightly constrain:
- Route and site: transmucosal delivery via buccal surface; mucoadhesive adherence.
- Material architecture: at least two distinct polymeric environments (diffusion environment and adjacent barrier environment), with optional additional layer.
- Microenvironment chemistry: diffusion environment pH window and buffering.
- Release physics: “unidirectional diffusion gradient” as a functional result of the layered structure upon application.
This structure tends to read on designs intended to promote controlled absorption across the buccal mucosa while reducing diffusion in the wrong direction (eg, lateral/contrary-side leakage).
What are the key claim limitations in independent claims 1, 13, and 25?
Claim 1 (method): delivering buprenorphine with pH 4–7.5 diffusion environment + barrier + unidirectional gradient
Claim 1 requires all of the following in combination:
- Administer a mucoadhesive biodegradable drug delivery device for transmucosal delivery.
- The device has a bioerodible mucoadhesive layer containing buprenorphine in a polymeric diffusion environment.
- Diffusion environment pH between about 4 and about 7.5.
- A polymeric barrier environment adjacent to the mucoadhesive layer.
- Unidirectional diffusion gradient of buprenorphine upon application to a buccal surface.
Functional elements that matter:
- “Unidirectional diffusion gradient” is a release-direction constraint. It is likely tied to a particular gradient setup (barrier layer plus diffusion layer design) that yields preferential directional flux.
Claim 13 (device): same architecture as claim 1, device form
Claim 13 mirrors claim 1 but as a device claim:
- Bioerodible mucoadhesive layer with buprenorphine in polymeric diffusion environment.
- Diffusion environment pH 4–7.5.
- Barrier environment adjacent to mucoadhesive layer.
- Unidirectional diffusion gradient upon application to buccal surface.
In litigation, device claims often create cleaner infringement theories for manufacturers than method claims, because the device can be compared to structural parameters. Here, the “unidirectional diffusion gradient upon application” may still inject a performance/functional component that defendants can argue is not met by their materials or design.
Claim 25 (method of treating pain): adherence + same device features + pH buffered
Claim 25 adds a therapeutic use framing:
- Adhere the device to buccal surface.
- Diffusion environment is pH buffered to 4–7.5.
- Barrier environment provides unidirectional gradient upon application.
So claim 25 likely depends on:
- The device being buffered within 4–7.5, not merely having pH in that range.
How do the dependent claims narrow scope: pH, polymer classes, antagonist in barrier, and third layer?
pH narrowing (claims 4, 8; buffered embodiments claims 7, 8, 19, 20)
- Claim 4 / 8: pH about 4 to about 6.
- Claim 7 / 19: pH buffered to between about 4 and about 7.5.
- Claim 8 / 20: pH buffered to between about 4 and about 6.
These dependent claims create a layered protection strategy:
- Broad independent coverage at 4–7.5 without explicit “buffered” language.
- Additional narrower claims cover buffering and a tighter pH window (4–6), which can be used to assert infringement against formulations engineered to stabilize pH.
Polymer composition dependencies (claims 2, 9, 14, 21)
- At least one film-forming water-erodible adhesive polymer and
- At least one bioadhesive polymer
in the polymeric diffusion environment.
This supports a prosecution-and-enforcement theme: not just any polymer environment qualifies; there are embodiments where the diffusion layer is designed as a film-forming, water-erodible adhesive matrix with bioadhesive character.
Barrier environment dependencies including an opioid antagonist (claims 5, 11, 17, 23)
- Barrier environment further comprises an opioid antagonist.
This introduces abuse-deterrence style coverage. Even though the dependent claim does not specify which opioid antagonist (naloxone is common in buprenorphine abuse-deterrent products), the claim requires that an opioid antagonist is part of the barrier environment.
It also means the patent landscape should track:
- Whether later competitors include antagonist-containing layers.
- Whether antagonist is in the barrier environment specifically (adjacent to the mucoadhesive layer) versus elsewhere.
Third layer/coating (claims 6, 12, 18, 24)
- Device further comprises a third layer or coating.
This creates coverage for more complex multilayer stacks. If a product uses a topcoat, backing, rate-controlling laminate, or additional protective film, it may fall within these dependent claims.
What products or design-archetypes are most likely to fall within the claim “zone”?
Based on the limitations you supplied, the highest-likelihood coverage group is:
- Buccal mucoadhesive biodegradable films/patches/gels containing buprenorphine,
- With an intentionally controlled local pH microenvironment in a diffusion matrix (4–7.5),
- Paired with an adjacent barrier layer that shapes diffusion directionality.
Key design features that map closely:
- Multilayer device where the buprenorphine-loaded adhesive matrix is adjacent to a barrier polymer layer intended to prevent drug back-diffusion or lateral migration.
- Formulation systems designed to keep pH in the diffusion environment (buffered or inherently within the range due to polymer/acid/base pairing).
Lower likelihood coverage (but not excluded by your text) includes systems that:
- Use non-buccal routes (sublingual only) without matching “buccal surface.”
- Use non-biodegradable polymers if the device is not “biodegradable.”
- Lack a distinct “barrier environment disposed adjacent” to the mucoadhesive layer.
How does US 9,655,843 compare to common buprenorphine buccal delivery patent themes?
Within buprenorphine transmucosal technology, patents often cluster around:
- Mucoadhesive polymers and patch design
- pH/pH buffering for mucosal compatibility and drug stability
- Controlled release and directional flux
- Abuse deterrence by antagonist co-formulation
US 9,655,843 combines those strands into one claim architecture:
- Directional release (“unidirectional diffusion gradient”)
- pH-window diffusion environment (4–7.5; optionally 4–6)
- Barrier environment adjacent to the mucoadhesive layer
- Optional antagonist in the barrier environment
That combination tends to be harder to design around than a patent limited to generic “mucoadhesion” or “buccal delivery” alone.
What is the likely claim coverage for formulations with naloxone or other antagonists?
The antagonist dependent claims are structurally specific:
- “polymeric barrier environment further comprises an opioid antagonist.”
So, if a competitor:
- Adds antagonist but places it within the buprenorphine mucoadhesive diffusion layer (not the barrier environment), it may avoid the dependent claim.
- Places antagonist in a barrier layer adjacent to mucoadhesive layer, it increases infringement risk for claims 5/11/17/23.
Also, the independent claims (1/13/25) do not require antagonist. So antagonist placement is relevant mainly to dependent claims and potential narrower assertions.
What design-around strategies are suggested by the claim language?
From the claim set alone, design-around attempts typically target one of the required elements:
- Remove/alter the “unidirectional diffusion gradient” mechanism
If a competitor’s release is more bidirectional or lacks a comparable gradient upon buccal application, infringement risk decreases. The “unidirectional diffusion gradient” language creates a performance boundary that can become the battleground via testing.
- Change diffusion environment pH outside 4–7.5
Moving above 7.5 or below 4 in the diffusion environment avoids the independent pH limitation.
For narrower claims, moving outside 4–6 or avoiding buffering may matter.
- Eliminate or materially change the adjacent “polymeric barrier environment”
If the device lacks a barrier layer adjacent to the mucoadhesive layer, the claim is not met.
- Change the route/site requirement
Avoid “buccal surface” delivery if claiming use of a different transmucosal site without matching claim language (this is route-specific, not just dose form).
- Substitute a non-biodegradable device
Claims require “biodegradable”/“bioerodible” materials in the device and mucoadhesive layer.
What does this imply for enforcement: methods vs devices vs therapeutic use?
- Device claims (13) are often the most enforceable against manufacturers because product comparison can be performed by structural and process evidence.
- Method claims (1 and 25) are enforceable against downstream parties involved in administration and use. Claim 25’s therapeutic “treating pain” adds use framing, which can overlap with clinical indications.
In practice, if the same device is manufactured and administered by multiple actors, the device claim can be asserted in parallel with method claims.
US patent landscape: how to map related claims and continuations around US 9,655,843
You asked for “detailed analysis of the scope and claims and patent landscape for United States Drug Patent 9,655,843,” but you provided only the claim text. Without the patent bibliographic record (inventors, assignee), prosecution history, and the patent family members, it is not possible to produce an accurate landscape that lists:
- related continuation patents,
- overlapping composition or method-of-use patents,
- Orange Book listings,
- Paragraph IV or biosimilar litigation risk,
- expiration dates and exclusivity windows,
- jurisdiction-by-jurisdiction coverage.
Per the constraints, no partial or fabricated landscape can be produced from the claim excerpt alone.
What can be extracted reliably from the claim text is the technical landscape position: this patent sits at the intersection of (i) buprenorphine transmucosal mucoadhesive biodegradable devices, (ii) pH-controlled diffusion microenvironments, and (iii) barrier-layer engineering to create directional drug flux, with optional abuse deterrence via opioid antagonist in barrier.
Key takeaways
- US 9,655,843 is built around a multilayer buccal mucoadhesive biodegradable device that drives a unidirectional buprenorphine diffusion gradient upon buccal application.
- pH is a core claim pillar: diffusion environment pH is 4–7.5 in the independent claims, with dependent claims narrowing to 4–6 and requiring buffering in certain dependent claims.
- Barrier-layer placement is material: a polymeric barrier environment adjacent to the mucoadhesive layer is required; dependent claims add an opioid antagonist in the barrier.
- Scope is both device and method: independent device claim 13 and method claim 1 share the same technical architecture; claim 25 adds a pain-treatment use with a buffered pH limitation.
- The most direct design-arounds target one required feature: diffusion pH window, unidirectional diffusion gradient behavior, barrier-layer adjacency, or the buccal route/site.
FAQs
1) Does US 9,655,843 require naloxone specifically?
No. The dependent claims require an “opioid antagonist” in the barrier environment but do not specify a particular antagonist in the claim text you provided.
2) Is buffering required in the independent claims?
No. Independent claims require a diffusion environment pH between about 4 and about 7.5; buffering is specified in dependent claim sets (claims referencing “pH buffered”).
3) What’s the difference between claims 1 and 13?
Claim 1 covers the method of delivering buprenorphine using the device. Claim 13 covers the device itself.
4) Can a three-layer or coated device avoid infringement?
No. The claims include dependent coverage for a device with a third layer or coating.
5) Which limitation is most likely to be contested in an infringement test?
The functional requirement of a “unidirectional diffusion gradient” upon application to the buccal surface is likely to drive performance testing and expert analysis.
References
- United States Patent No. 9,655,843. Claims as provided in the prompt.
